Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Promitil in BRCA-mutated ovarian and pancreatic cancer
NCT06478862Phase 2Terminated
- Sponsor
- LipoMedix
- Start
- Jun 2024
- Primary completion
- Jan 2026
- Modality
- Lipid-based Nanoparticles, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Mitomycin-c lipidic prodrug in ovarian cancer and pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by LipoMedix. Primary endpoint: Progression-Free Survival rate at Month 6. Started Jun 2024; status: terminated.
02
Drugs
Mitomycin-c lipidic prodrug
03
Conditions
ovarian cancerpancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06478862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06478862.